(149 days)
No
The document explicitly states that the DeltaScan Patch does not contain software and its function is solely to acquire and transfer EEG signals. The signal analysis is performed by the separate DeltaScan Monitor (K222680), which is not described in this summary.
No.
The device is described as an EEG electrode patch used to record EEG signals, which are then analyzed by a separate monitor. It is a diagnostic tool, not one that provides therapy.
Yes
The device, the DeltaScan Patch, is used with the DeltaScan Monitor to enable the acquisition of EEG signals. The DeltaScan Monitor then provides signal analysis technology intended for use as an adjunct to clinical judgment. While the patch itself is for signal acquisition, its stated purpose in conjunction with the monitor is for signal analysis as an adjunct to clinical judgment, which points to a diagnostic intent.
No
The device description explicitly states that the DeltaScan Patch is a single-use EEG electrode patch and does not contain software. It is a hardware component used to acquire EEG signals.
Based on the provided information, the DeltaScan Patch is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the examination of specimens derived from the human body (such as blood, urine, or tissue) to provide information for diagnostic purposes.
- DeltaScan Patch Function: The DeltaScan Patch is applied directly to the patient's skin to record electrical signals (EEG). It does not analyze or process specimens derived from the body. Its function is to acquire physiological signals from the patient's surface.
- Intended Use: The intended use is to record EEG signals from the patient's skin, not to analyze bodily fluids or tissues.
- Device Description: The description clearly states it's an EEG electrode patch used to collect EEG signals.
Therefore, the DeltaScan Patch falls under the category of a medical device that interacts with the patient's body to acquire physiological data, rather than an IVD device that analyzes specimens.
N/A
Intended Use / Indications for Use
The DeltaScan Patch is applied directly to the patient's skin to record EEG signals.
The DeltaScan Patch is dedicated and only intended to be used in combination with the DeltaScan Monitor (K222680) through a proprietary connector design.
Product codes (comma separated list FDA assigned to the subject device)
GXY
Device Description
The DeltaScan Patch is a single use EEG electrode Patch, used exclusively with the DeltaScan Monitor. The DeltaScan Patch is used with the DeltaScan Monitor to enable the acquisition of EEG signals. The DeltaScan Monitor provides signal analysis technology intended for use as an adjunct to clinical judgment.
The DeltaScan Patch is used to collect EEG signals from two electrode locations see Figure 5-1 DeltaScan Patch Electrode Locations.
The 1st electrode is placed on or close . to Pz (on the crown of the head)
a second electrode on or close to Fp2 (above the patient's right eyebrow
0 a third (Reference) electrode on or close to Fpz (above the nose on the forehead)
Pz, Fp2 and Fpz refer to defined EEG electrode locations in the standard 10/20 EEG setup
The DeltaScan Patch electrode buildup (see Figure 5-2) consists of:
- a polyurethane foam sponge with conductive wet EEG gel and tines to reduce impedance
- a carrier (substrate) of flexible PET foil (Melinex)
- a medical grade adhesive foam around the electrodes for adherence to the skin
- the conductive silver tracks and silver /silver chloride electrodes provide signal continuity from the electrode (gel, foam, tine) to the monitor
- isolation layer covering the silver ink tracks of the printed electrodes is used to restrict electrical contact to the electrode area
- hydrogel anchors for improved adherence to the head and for stability
- the reinforced connector is a dedicated mechanism to interface with the Monitor.
The body of the sensor houses two (2) electrodes which are placed on the forehead, and a third electrode at the area on the crown of the head (Pz location).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
patient's skin (specifically, on or near Pz (crown of the head), Fp2 (above the patient's right eyebrow), and Fpz (above the nose on the forehead))
Indicated Patient Age Range
adults over 60 years of age.
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Biocompatibility testing: The biocompatibility evaluation for the DeltaScan Patch was assessed in accordance with the FDA's guidance document titled, "Use of International Standard ISO 10993-1, 'Biological Evaluation of Medical Devices Part 1: Evaluation and testing within a risk management process", June 16, 2016. All parts of the DeltaScan Patch R2 with REF 009.000.B that are directly in contact with the patient's skin have passed the acceptance criteria defined per ISO 10993-1:2018 requirements.
Electrical safety and electromagnetic compatibility (EMC): In accordance with the EN ISO 60601-1, the use of the DeltaScan Patch does not depend on essential performance. The DeltaScan Patch is not considered Medical Electrical Equipment as defined by the EN ISO 60601-1.
Software verification and validation testing: N/A as the DeltaScan Patch does not contain software.
Mechanical testing:
- The labels on the packaging were tested to verify be legible, durable, compliant with regulations, and compatible with the packaging.
- The packaging was tested to verify to be compatible with the labeling, and can be shipped without damage.
The 'Label and IfU review report' is provided in this 510(k) and the Shipping Validation Report DeltaScan Patch is provided in this 510(k).
Shelf life: The DeltaScan Patch has a stated shelf life of 9 months. These 9 months are mainly based on the degradation of the two frontal electrodes, being the most critical part for shelf life of the DeltaScan Patch. This is verified and documented in the Verification Report based on accelerated aging. Real time aging is still in progress and may in future demonstrate a longer shelf life.
Clinical Studies: The Verification Report provides sufficient proof that it transfers the electrical signals as intended. No dedicated clinical study is needed to validate the device performance. The data in the Verification Report for the DeltaScan Patch shows that it performs as intended, is safe and effective for its intended use, and provides similar safety and effectiveness results to the predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 882.1320 Cutaneous electrode.
(a)
Identification. A cutaneous electrode is an electrode that is applied directly to a patient's skin either to record physiological signals (e.g., the electroencephalogram) or to apply electrical stimulation.(b)
Classification. Class II (performance standards).
0
February 2, 2023
Image /page/0/Picture/1 description: The image shows the logos of the Department of Health and Human Services and the U.S. Food and Drug Administration (FDA). The Department of Health and Human Services logo is on the left, and the FDA logo is on the right. The FDA logo is a blue square with the letters "FDA" in white. To the right of the square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Prolira B.V. % Dr. Paul Manberg Corolla Clin/Reg Consulting 481 Spindrift Trail #696 Corolla, North Carolina 27927
Re: K222671
Trade/Device Name: DeltaScan Patch Regulation Number: 21 CFR 882.1320 Regulation Name: Cutaneous Electrode Regulatory Class: Class II Product Code: GXY Dated: August 25, 2022 Received: September 6, 2022
Dear Paul Manberg:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerelv.
Jay R. Gupta -S
Jay Gupta Assistant Director DHT5A: Division of Neurosurgical, Neurointerventional and Neurodiagnostic Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K222671
Device Name DeltaScan Patch
Indications for Use (Describe)
The DeltaScan Patch is applied directly to the patient's skin to record EEG signals.
The DeltaScan Patch is dedicated and only intended to be used in combination with the DeltaScan Monitor (K222680) through a proprietary connector design.
Please refer to the Instructions for Use and the Instructions for Use on the Primary packaging of the DeltaScan Patch for more information.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with 21 CFR 807.92.
SUBMITTER l.
Prolira BV Padualaan 8 Utrecht, The Netherlands NL-3584 CH Phone Number: +31 6 47762936 Email: r.vanmerkerk@prolira.com
Contact Person: Rutger van Merkerk Date Prepared: August 25, 2022, date updated 05-Jan-2023
II. DEVICE
Name of Device: DeltaScan Patch Common or Usual Name: DeltaScan Patch Classification Name: Cutaneous electrode (21 CFR 882.1320). Regulatory Class: II Product Code: GXY
III. PREDICATE DEVICE
| Name | Manufacturer | 510(k) # |
|---|---|---|
| Covidien BIS Sensors (BIS Quatro Sensor, BIS | ||
| Extend, BIS Pediatric Sensor, BIS Bilateral Sensor) | COVIDIEN | K143506 |
IV. DEVICE DESCRIPTION
The DeltaScan Patch is a single use EEG electrode Patch, used exclusively with the DeltaScan Monitor. The DeltaScan Patch is used with the DeltaScan Monitor to enable the acquisition of EEG signals. The DeltaScan Monitor provides signal analysis technology intended for use as an adjunct to clinical judgment.
The DeltaScan Patch is used to collect EEG signals from two electrode locations see Figure 5-1 DeltaScan Patch Electrode Locations.
4
Image /page/4/Figure/2 description: The image shows a diagram of the human head with various points labeled, likely representing electrodes for an EEG. Key points such as 'Fpz (ref)', 'Fp2', and 'Pz' are highlighted with arrows pointing to their respective locations on the head. Other points like 'F1', 'F3', 'F4', 'F8', 'A1', 'T3', 'C3', 'C4', 'T4', 'A2', 'P3', 'P4', 'TS', 'T6', '01', and '02' are also labeled, indicating a comprehensive mapping of the head's surface.
Figure 5-1 DeltaScan Patch Electrode Locations
- The 1st electrode is placed on or close . to Pz (on the crown of the head)
- . a second electrode on or close to Fp2 (above the patient's right eyebrow
- 0 a third (Reference) electrode on or close to Fpz (above the nose on the forehead)
Pz, Fp2 and Fpz refer to defined EEG electrode locations in the standard 10/20 EEG setup
Image /page/4/Figure/8 description: This image shows a diagram of a flexible EEG sensor patch. The patch has an adhesive foam for adherence to the skin on the forehead. There are two hydrogel anchors for improved adherence to the head and for stability. The patch has a butterfly shape to realize a one-size-fits-all design for different head sizes.
For a depiction of the main components, see Figure 5-2 below:
In designing the DeltaScan Patch, the International 10-20 System was used as a basis for electrode placement. Two recording electrodes are placed on the Fp2 and Pz locations, while the reference electrode is placed at the Fpz location, see Figure 5-1 DeltaScan Patch Electrode
Figure 5-2 Product overview
5
Locations above. The electrodes are individually packaged and pre-gelled. The DeltaScan Monitor should only be used in combination with a DeltaScan Patch, see Figure 5-3.
Image /page/5/Picture/3 description: The image shows a diagram of a medical device called PROLIRA DELTASCAN. The device consists of a head-mounted sensor array connected by a cable to a control unit. The head-mounted sensor array is positioned on the head, and the control unit has a display screen and buttons. The device is likely used for brain monitoring or diagnostics.
Figure 5-3: Artist impression of the DeltaScan Monitor used with a DeltaScan Patch
V. INDICATIONS FOR USE
The DeltaScan Patch is applied directly to the patient's skin to record EEG signals.
The DeltaScan Patch is dedicated and only intended to be used in combination with the DeltaScan Monitor (K222680) through a proprietary connector design.
Please refer to the Instructions for Use and the Instructions for Use on the Primary packaging of the DeltaScan Patch for more information.
- VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE Like the predicate, the DeltaScan Patch is applied directly to the patient's skin to enable recordings of EEG signals.
The BIS Sensor with submission number K143506 is suggested as the most appropriate predicate device.
A technology comparison is provided in Table 5-1 below.
6
| Table 5-1 technology comparison | |
|---|---|
| BIS Sensor | DeltaScan Patch |
| Intended Use | |
| Electrode, Cutaneous Electrode | Electrode, Cutaneous Electrode |
| Indications for Use | |
| Electrode that is applied directly to a patient's skin | |
| to record EEG signals. | The DeltaScan Patch is an electrode that is applied |
| directly to a patient's skin to record EEG signals. | |
| The DeltaScan Patch is intended to be used in | |
| Note: used in conjunction with Covidien BIS | |
| Monitors. | combination with the DeltaScan Monitor (K222680) |
| through a proprietary connector design. | |
| Please refer to the Instructions for Use on the | |
| Primary packaging of the DeltaScan Patch and the | |
| Instructions for Use of the DeltaScan Monitor for | |
| more information. | |
| LIMITATIONS | LIMITATIONS |
| For prescription use only. | For prescription use only. |
| Single use | Single use |
| Only to be used with the BIS Monitor | Only to be used with the DeltaScan Monitor |
| Refers to the labeling for a more complete list of | Refers to the labeling for a more complete list of |
| Warnings, Precautions and Contraindications. | Warnings, Precautions and Contraindications. |
| Primary EEG Feature/Electrode position | |
| It is a low impedance, single patient use, disposable | |
| electrode sensor | It is a low impedance, single patient use, disposable |
| electrode sensor | |
| The "zipprep" design is constructed using flexible | |
| tine disks placed in pockets on a polyethylene | |
| basepad. A polyurethane foam disk and hydrogel is | |
| placed over the tines. The basepad has a medical | |
| grade pressure sensitive adhesive for adhering to | |
| the skin. A mylar substrate with conductive silver / | |
| silver chloride ink circuit is adhered to the other | |
| side of the base pad. The flexible tines, surrounded | |
| by hydrogel, are used to part the outermost layer of | |
| skin. While the flexible tines part the skin, hydrogel | |
| flows around the tines and forms a conductive | |
| bridge with the skin. The silver / silver chloride | |
| circuit provides signal continuity from each | |
| electrode (gel/tine/foam) to the monitor. A | |
| polyester insulation is used to restrict electrical | |
| contact to the electrode area. | Equivalent |
| The DeltaScan Patch electrode buildup (see Figure | |
| 5-2) consists of: |
- a polyurethane foam sponge with conductive
wet EEG gel and tines to reduce impedance - a carrier (substrate) of flexible PET foil
(Melinex) - a medical grade adhesive foam around the
electrodes for adherence to the skin - the conductive silver tracks and silver /silver
chloride electrodes provide signal continuity
from the electrode (gel, foam, tine) to the
monitor - isolation layer covering the silver ink tracks of
the printed electrodes is used to restrict
electrical contact to the electrode area - hydrogel anchors for improved adherence to
the head and for stability - the reinforced connector is a dedicated
mechanism to interface with the Monitor. |
| BIS Sensor | DeltaScan Patch |
| | Equivalent |
| The body of the sensor houses three (3) electrodes | The body of the sensor houses two (2) electrodes |
| which are placed on the forehead, and a fourth | which are placed on the forehead, and a third |
| electrode placed over the temple area. | electrode at the area on the crown of the head (Pz |
| | location). |
| Software | |
| N/A | N/A |
| Device Output | |
| | Equivalent |
| The sensor collects EEG signals and these are used | The sensor collects EEG signals and these are used |
| to calculate the Bispectral Index (BIS) value by the | to calculate the DeltaScan Output by the DeltaScan |
| BIS Monitor. | Monitor. |
Tahle 5-1 te -1 ...
7
VII. PERFORMANCE DATA
The following performance data were provided in support of the substantial equivalence determination.
Biocompatibility testing
The biocompatibility evaluation for the DeltaScan Patch was assessed in accordance with the FDA's guidance document titled, "Use of International Standard ISO 10993-1, 'Biological Evaluation of Medical Devices Part 1: Evaluation and testing within a risk management process", June 16, 2016.
The DeltaScan Patch is only worn by hospitalized adult patients (e.g., in the intensive care unit (ICU), cardiothoracic postoperative ward or geriatric traumatology ward) (see Figure 5-3) during a DeltaScan measurement². Such measurement potentially takes place once per 8 hours and has a duration of approx. 4 minutes (worst case 3x 10 minutes per 24 hours) and potentially on 3 to 5 consecutive days. Therefore, the DeltaScan Patch is a so called "surface contacting device" (contact with intact skin) with a limited duration (4 DeltaScan Monitor is Indicated for adults over 60 years of age.
8
Electrical safety and electromagnetic compatibility (EMC)
In accordance with the EN ISO 60601-1, the use of the DeltaScan Patch does not depend on essential performance. The DeltaScan Patch is not considered Medical Electrical Equipment as defined by the EN ISO 60601-1.
Software verification and validation testing
N/A as the DeltaScan Patch does not contain software.
Mechanical testing
- The labels on the packaging were tested to verify be legible, durable, compliant with regulations, and compatible with the packaging.
- The packaging was tested to verify to be compatible with the labeling, and can be shipped without damage.
The 'Label and IfU review report' is provided in this 510(k) and the Shipping Validation Report DeltaScan Patch is provided in this 510(k).
Shelf life
The DeltaScan Patch has a stated shelf life of 9 months. These 9 months are mainly based on the degradation of the two frontal electrodes, being the most critical part for shelf life of the DeltaScan Patch. This is verified and documented in the Verification Report based on accelerated aging.
Real time aging is still in progress and may in future demonstrate a longer shelf life.
Clinical Studies
The Verification Report provides sufficient proof that it transfers the electrical signals as intended. No dedicated clinical study is needed to validate the device performance.
The data in the Verification Report for the DeltaScan Patch shows that it performs as intended, is safe and effective for its intended use, and provides similar safety and effectiveness results to the predicate device.
VIII. CONCLUSION
Based on the intended use, technological characteristics, and performance data provided in this premarket notification, the subject device has been shown to be substantially equivalent to the currently marketed predicate device.